ESTIMATION OF THE EFFECTIVENESS OF FINANCIAL COSTS FOR TARGETED THERAPY OF PATIENTS WITH METASTATIC KIDNEY CANCER

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2018-64-5-657-663

Published 01.05.2018

Lyudmila Gurina⁺⁻
Galina Alekseeva⁺⁻
Lyubov Pisareva⁺⁻
Mikhail Volkov⁺⁻
Ye. Yevtushenko⁺⁻

Lyudmila Gurina

Primorsky Regional Oncology Center

Galina Alekseeva

Vladivostok State Medical University

Lyubov Pisareva

Cancer Research Institute, Tomsk National Research Medical Center

Mikhail Volkov

Primorsky Regional Oncology Center

Ye. Yevtushenko

Primorsky Regional Oncology Center

##article.numberofdownloads## 46

##article.numberofviews## 54

PDF (Русский)

Keywords

TARGETED THERAPY
KIDNEY CANCER
SUNITINIB
SORAFENIB
EVEROLIMUS
AXITINIB
MAXIMUM SURVIVAL

How to Cite

Gurina, L., Alekseeva, G., Pisareva, L., Volkov, M., & Yevtushenko, Y. (2018). ESTIMATION OF THE EFFECTIVENESS OF FINANCIAL COSTS FOR TARGETED THERAPY OF PATIENTS WITH METASTATIC KIDNEY CANCER. Voprosy Onkologii, 64(5), 657–663. https://doi.org/10.37469/0507-3758-2018-64-5-657-663

Abstract

Targeted therapy significantly increases the survival of patients with metastatic kidney cancer. The additional costs when transferring patients with metastatic kidney cancer to sequential therapy according to the scheme of sunitinib-axitinib are economically highly effective and allow achieving maximum survival.

https://doi.org/10.37469/0507-3758-2018-64-5-657-663

##article.numberofdownloads## 46

##article.numberofviews## 54

PDF (Русский)

References

Куликов А.Ю. Фармакоэкономическая оценка лекарственных средств эрлотиниб, доцетаксел, пеметрексед и гефитиниб в терапии второй линии местно-распространенного или метастатического немелкоклеточного рака легкого // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. - 2012. - № 3. - С. 8-12.

Ягудина, Р.И., Серпик, В.Г, Сороковиков, И.В. Методологические основы анализа «затраты -эффективность» // Фармэкономика: Теория и практика. - 2014. - Т. 2. - № 1. - С. 23-27.

Ягудина, Р.И., Серпик, В.Г. Методологические основы фармакоэкономического моделирования // Фармэкономика: Теория и практика. - 2016. - Т. 4. - № 1. - С. 7-12.

Brian I. Rini. Comparative effectiveness of axitinib vs sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial // Published Online November 4. - 2011. - Vol. (11)6. - P 1613-1619. - http:// 10.1016/ S0140-6736 DOI: 10.1016/S0140-6736

Escudier B., Szczylik C., Hutson T.E. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma // J. Clin. Oncol. - 2009. - Vol. 27(8). - Р 1280-1289

Motzer, R. J, Hutson, T., Tomczak, P. et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma // New England Journal of Medicine. - 2007. - Vol. 356. - № 2. - Р 115-124

Motzer, R.J. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Final results and analysis of prognostic factors // J. Cancer. - 2010. - Vol. 116. - P. 4256-4265.

Motzer R.J. Sunitinib in patients with metastatic renal cell carcinoma // JAMA. - 2006. -Vol. 7; 295(21). Р 2516-24.

Motzer, R.J., et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma // J. of Clinical Oncology. - 2009. - Vol. 27. - № 22. - P 3584 - 3590.

Motzer, R.J., Michaelson, M.D., Redman, B.G. et al. SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, demonstrates antitumor activity in patients with metastatic renal cell carcinoma // J. Clin. Oncol. - 2006. - Vol. 24. - P 16-24.

Motzer, R.J. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial // J. Lancet Oncol. - 2013. - Vol.14. - P. 552-62.

http://www.gks.ru/wps/wcm/connect/rosstat_main/ rosstat/ru/statistics/population/demography/#.

http://www.gks.ru/wps/wcm/connect/rosstat_main/ rosstat/ru/statistics/accounts/#.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Lyubov Pisareva, Nina Lyakhova, Yelena Panferova, Irina Odintsova, Olga Ananina, Tatyana Chimitdorzhieva, Artem Doroshenko, Nadezhda Cherdyntseva, D. Perinov, EPIDEMIOLOGICAL ASPECTS OF BREAST CANCER IN THE REPUBLIC OF BURYATIA. WAYS OF PREVENTION , Voprosy onkologii : Vol. 64 No. 2 (2018)
Yevgeniy Choynzonov, Lyubov Pisareva, Liliya Zhuykova, Olga Ananina, Irina Odintsova, INCIDENCE OF RESPIRATORY SYSTEM CANCER IN THE TOMSK REGION (2005-2016) , Voprosy onkologii : Vol. 64 No. 6 (2018)
Yuliya Kzhyshkovska, Nadezhda Cherdyntseva, Sergey Tuzikov, Lyubov Pisareva, Marina Ibragimova, Sergey Miller, Irina Deryusheva, Yevgeniy Rodionov, Matvey Tsyganov, Nikolay Litvyakov, PROGNOSTIC SIGNIFICANCE OF MONORESISTANCE GENE EXPRESSION IN TUMORS OF PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PREOPERATIVE CHEMOTHERAPY , Voprosy onkologii : Vol. 63 No. 1 (2017)